Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Wasting syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    49 result(s) found for: Wasting syndrome. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2006-004420-37 Sponsor Protocol Number: 280 Start Date*: 2007-05-29
    Sponsor Name:OSIRIS
    Full Title: ﾓA Phase III, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymalﾙ (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment o...
    Medical condition: Subjects must have steroid refractory treatment of Grades B-D acute GVHD secondary to allogeneic HSCT (stem cells sources: bone marrow, peripheral blood stem cells, or cord blood cells) or DLI.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018651 Graft versus host disease LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004118-33 Sponsor Protocol Number: trapiantoover66 Start Date*: 2013-06-17
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE)
    Full Title: High-dose cyclophosphamide role in the prophylaxis of GVHD in elderly patients (66-70 years) with acute leukemia or myelodysplasia high-risk, submitted to allogenic transplant of peripheral hematop...
    Medical condition: Elderly patients (66-70 years) with acute leukemia or high-risk MDS who, underwent allogenic transplant of peripheral hematopoietic progenitors after reduced-intensity conditioning.
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004870 10018653 Graft-versus-host disease LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001925-27 Sponsor Protocol Number: 06-MI-04 Start Date*: 2009-10-05
    Sponsor Name:Great Ormond Street Hospital For Children NHS Trust
    Full Title: Phase I/II clinical trial of T cell suicide gene therapy following haploidentical stem cell transplantation
    Medical condition: Graft-versus-host disease (GVHD) resulting from haploidentical bone marrow or blood stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018651 Graft versus host disease LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-006178-86 Sponsor Protocol Number: EBMT-LE-0601 Start Date*: 2007-08-03
    Sponsor Name:European group for Blood and Marrow Transplantation
    Full Title: A randomized placebo-controlled trial comparing cyclosporine plus steroids with or without Myfortic® as primary treatment for extensive chronic graft-versus host disease
    Medical condition: patients with newly diagnosed (first episode) extensive chronic Graft versus Host Disease (cGvHD) post allogeneic transplantation for any primary diagnosis
    Disease: Version SOC Term Classification Code Term Level
    7 10018651 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) ES (Ongoing) SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003674-14 Sponsor Protocol Number: CSM/EICH2005 Start Date*: 2007-01-19
    Sponsor Name:Mª Consuelo del Cañizo Fernández-Roldán
    Full Title: Ensayo clínico en fase I/II de tratamiento de EICH refractaria mediante la infusión de células mesenquimales alogénicas expandidas in vitro / A Phase I/II clinical trial for the treatment of refrac...
    Medical condition: Enfermedad injerto contro huésped / Graft-versus-host disease
    Disease: Version SOC Term Classification Code Term Level
    9.0 10018651 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003005-14 Sponsor Protocol Number: GVHD 1 Start Date*: 2010-12-30
    Sponsor Name:ASSOCIAZIONE MALATTIE SANGUE
    Full Title: Antimicotyc prophylaxis with Amphotericina B in lypidic complex aerosol in GVHD patients under steroid treatment
    Medical condition: GVHD patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018799 GVHD LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001550-14 Sponsor Protocol Number: ECP-GVHD1 Start Date*: 2015-06-09
    Sponsor Name:Bispebjerg hospital
    Full Title: Extracorporeal Photopheresis Treatment in steroid refractory acute and chronic Graft versus Host Disease
    Medical condition: Acute and chronic Graft versus Host Disease (GVHD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021428 - Immune system disorders 10018651 Graft versus host disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001508-19 Sponsor Protocol Number: IMA-GVH Start Date*: 2007-09-06
    Sponsor Name:AZIENDA OSPEDALIERA S. CARLO
    Full Title: TRATTAMENTO CON IMATINIB MESILATO DELLA GVH CRONICA SEVERA SCLERODERMA-LIKE REFRATTARIA ALLA TERAPIA IMMUNOSOPRESSIVA CONVENZIONALE
    Medical condition: GVH CRONICA ESTESA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018651 Graft versus host disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004067-53 Sponsor Protocol Number: Thymo-06 Start Date*: 2006-09-05
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: A multicenter randomized study on the use of rabbit anti-T-Lymphocite globulin ATG different doses to prevent GVHD in children receiving allogenic stem cell transplantation
    Medical condition: ematological malignant neoplasm
    Disease: Version SOC Term Classification Code Term Level
    6.1 10018651 PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001892-12 Sponsor Protocol Number: 00557 Start Date*: 2007-10-15
    Sponsor Name:University Medical Centre Freiburg
    Full Title: Everolimus and mycophenolate as GvHD-prophylaxis in the allogenous blood stem cell transplantation (Everolimus und Mycophenolsäure als GvHD-Prophylaxe in der allogenen Blutstammzelltransplantation)
    Medical condition: Prophylaxis of graft-versus-host disease after allogenous blood stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018799 GVHD LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005809-21 Sponsor Protocol Number: ADN-GVHD vs BT 5/9 Start Date*: 2008-06-06
    Sponsor Name:FONDAZIONE RICERCA TRAPIANTO DI MIDOLLO OSSEO
    Full Title: Treatment of Steroid refractory Graft versus Host Disease with monoclonal antibody B T 5/9 (anti-CD26)
    Medical condition: patients with acute GVHD not responsive
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018651 Graft versus host disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023279-25 Sponsor Protocol Number: AloVita Start Date*: 2011-02-24
    Sponsor Name:José Antonio Pérez Simón
    Full Title: Efecto inmunomodulador de la vitamina D postrasplante alogénico: Ensayo clínico fase I-II multicéntrico
    Medical condition: Enfermedad Injerto contra Hésped en trasplante alogénico de médula ósea.
    Disease: Version SOC Term Classification Code Term Level
    13 10018651 Enfermedad del injerto contra el huésped LLT
    13 10059041 Trasplante alogénico periférico de células madre hematopoyéticas LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000101-11 Sponsor Protocol Number: ProfGVHD Start Date*: 2008-04-02
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: Multicenter, prospective, randomized clinical trial to assess two different doses of anti-human-T-lymphocyte immune serum preparation derived from rabbit in GVHD profilaxis in pediatric population ...
    Medical condition: graft versus host disease profilactic use
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018653 Graft-versus-host disease LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005019-81 Sponsor Protocol Number: INO-0106 Start Date*: 2006-12-22
    Sponsor Name:OPi
    Full Title: A European Open-Label, Multicentre, Phase II Study of Inolimomab in the Treatment of Primary Steroid Resistant Acute Graft versus Host Disease (aGvHD) following allogeneic Stem Cell Transplantation...
    Medical condition: For treatment of patients with Primary Steroid Resistant Acute Graft versus Host Disease (aGvHD) following allogeneic Stem Cell Transplantation for Hematological Malignancies in Adult patients
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018651 Graft versus host disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022780-35 Sponsor Protocol Number: 10-005 Start Date*: 2011-07-06
    Sponsor Name:THERAKOS, Inc.
    Full Title: A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy with UVADEX™ for the Treatment of Patients with Moderate to Severe Chronic Graft-versus-Host Disease (cGvHD)
    Medical condition: Chronic graft-versus-host disease (cGvHD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10018651 Graft versus host disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) AT (Completed) ES (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2021-004529-57 Sponsor Protocol Number: EQ-100-02 Start Date*: 2022-06-24
    Sponsor Name:Equillium Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease
    Medical condition: Acute Graft Versus Host Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10018799 GVHD LLT
    22.0 100000004865 10059044 Allogeneic peripheral hematopoietic stem cell transplant LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004847-35 Sponsor Protocol Number: PredEver_first Start Date*: 2012-09-07
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first) - A prospective multicenterphase IIA study -
    Medical condition: chronic Graft versus Host Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10018799 GVHD LLT
    14.1 10021428 - Immune system disorders 10063109 Transfusion associated GVHD LLT
    14.1 10021428 - Immune system disorders 10068907 CGVHD LLT
    14.1 10021428 - Immune system disorders 10018653 Graft-versus-host disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000894-22 Sponsor Protocol Number: MAGIC-HR-ECP Start Date*: 2019-12-10
    Sponsor Name:Department of Stem Cell Transplantation - University Medical Center Hamburg-Eppendorf
    Full Title: Phase II multicenter study of extracorporeal photopheresis with UvadexTM plus standard steroid treatment for high risk acute Graft-versus-Host Disease
    Medical condition: New onset high risk acute GvHD following allogeneic SCT
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10018653 Graft-versus-host disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002503-26 Sponsor Protocol Number: X16082 Start Date*: 2017-03-14
    Sponsor Name:Fundación Pública Andaluza para la Gestión en Salud de Sevilla (FISEVI)
    Full Title: Phase Ib/II trial to evaluate safety and efficacy of oral ixazomib in combination with sirolimus and tacrolimus in the prophylaxis of chronic graft-versus-host disease
    Medical condition: Adult patiens after allogeneic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004870 10018653 Graft-versus-host disease LLT
    19.1 100000004865 10067859 Allogenic stem cell transplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018594-37 Sponsor Protocol Number: EMN-alloRIC2010 Start Date*: 2013-01-24
    Sponsor Name:European Myeloma Network
    Full Title: European Myeloma Network sequential phase I / phase II trial on RIC allogeneic transplantation: an optimized program for high risk relapsed patients
    Medical condition: Allogeneic transplantation for patients with multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10059041 Allogeneic peripheral haematopoietic stem cell transplant LLT
    14.1 10021428 - Immune system disorders 10018651 Graft versus host disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 12:16:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA